Professional
Added to YB: 2025-12-01
Pitch date: 2025-11-26
ILA.AX [neutral]
Island Pharmaceuticals Limited
-39.29%
current return
Author Info
Research as a Service is Australia’s leading independent investment research house sharing institutional-quality, issuer-sponsored research. Sign up for the newsletter.
Company Info
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States.
Market Cap
AUD 108.1M
Pitch Price
AUD 0.56
Price Target
1.14 (+235%)
Dividend
N/A
EV/EBITDA
-9.31
P/E
-10.02
EV/Sales
336.82
Sector
Pharmaceuticals
Category
special_situation
Island Pharmaceuticals (ASX:ILA) - De-risking the commercial path
ILA.AX (update): Antiviral therapeutics targeting infectious diseases. Hired DC lobbying firm Todd Strategy Group & joined Medical Countermeasures Coalition to boost US gov't sales of Galidesivir for Marburg ahead of FDA clearance. Key risk mitigation as efficacy strong but being overlooked main commercial risk. rNPV price target $1.14/share.
Read full article (3 min)